top of page

FDA grants QIDP for C. Difficile IV treatment

Morphochem announced today that the U.S. Food and Drug Administration (FDA) has designated Morphochem’s intravenous antibacterial product candidate MCB3837 as a qualified infectious disease product (QIDP) for the treatment of Clostridium difficile infection, also known as CDI or C.Difficile.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page